Cancer Supportive Care Drug Development Pipeline Review, 2017

  • ID: 4434629
  • Report
  • 128 pages
  • GBI Research
1 of 5

Anorexia is defined as the loss of the desire to eat. Progressive wasting is common in many types of cancer and is one of the most important factors leading to early death in cancer patients. Advanced cancer undergo a wasting syndrome associated with cancer anorexia-cachexia and asthenia, which is associated with weakness, fatigue, and a poor quality of life. There are a total of 24 products in development for this indication, by 18 companies and four academic institutions.

Bone metastasis occurs when cancer cells spread from their original site to a bone. Signs and symptoms of bone metastasis include bone pain, broken bones, urinary incontinence, bowel incontinence and weakness in the legs. There are a total of 32 products in development for this indication, by 22 companies and four academic institutions. Key companies operating in this pipeline space include MetCure Therapeutics, Applied Integrin Sciences, Eli Lilly, and Tel Aviv University.

Cancer pain can be defined as a complex sensation that reflects both damage to the body and the body's response to the damage. Pain may arise due to tumor compressing or infiltrating tissue, from treatments and diagnostic procedures, or from skin, nerve and other changes caused by either the body's immune response or hormones released by the tumor. There are a total of 52 products in development for this indication, by 40 companies and four academic institutions. Key companies operating in this pipeline space include Komipharm, Trillium Therapeutics, AstraZeneca, Insys Therapeutics, Klaria Pharma and Pharmaleads.

The majority of products in cancer anorexia-cachexia syndrome target the growth hormone secretagogue receptor type 1, although there are a range of other molecular targets in development. Within bone metastasis, the most common molecular targets are the tumor necrosis factor ligand superfamily member 11, and the hepatocyte growth factor receptor, along with a range of others. Finally, within cancer pain, neurotransmitters such as the mu type opioid receptor, and a range of ion channels, are the most common type of target, reflecting the pain treatment landscape in general.

This report provides an overview of the Cancer Supportive Care pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for cancer anorexia-cachexia syndrome, bone metastasis and cancer pain, and features dormant and discontinued projects.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
READ MORE
Note: Product cover images may vary from those shown
2 of 5

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Cancer Supportive Care Report Coverage
2.2 Cancer Anorexia-Cachexia Syndrome – Overview
2.3 Bone Metastasis – Overview
2.4 Cancer Pain – Overview

3 Therapeutics Development
3.1 Cancer Anorexia-Cachexia Syndrome
3.2 Bone Metastasis
3.3 Cancer Pain

4 Therapeutics Assessment
4.1 Cancer Anorexia-Cachexia Syndrome
4.2 Bone Metastasis
4.3 Cancer Pain

5 Companies Involved in Therapeutics Development
5.1 Cancer Anorexia-Cachexia Syndrome
5.2 Bone Metastasis
5.3 Cancer Pain

6 Dormant Projects
6.1 Cancer Anorexia-Cachexia Syndrome
6.2 Bone Metastasis
6.3 Cancer Pain

7 Discontinued Products
7.1 Cancer Anorexia-Cachexia Syndrome
7.2 Bone Metastasis
7.3 Cancer Pain

8 Product Development Milestones
8.1 Cancer Anorexia-Cachexia Syndrome
8.2 Bone Metastasis
8.3 Cancer Pain

9 Appendix
9.1 Methodology
9.2 Coverage
9.3 Secondary Research
9.4 Primary Research
9.5 Expert Panel Validation
9.6 Contact Us
9.7 Disclaimer

List of Tables
Table 1: Number of Products under Development for Cancer Anorexia-Cachexia Syndrome
Table 2: Number of Products under Development by Companies, Cancer Anorexia-Cachexia Syndrome
Table 3: Number of Products under Development by Universities/Institutes, Cancer Anorexia-Cachexia Syndrome
Table 4: Products under Development by Companies, Cancer Anorexia-Cachexia Syndrome
Table 5: Products under Development by Universities/Institutes, Cancer Anorexia-Cachexia Syndrome
Table 6: Number of Products under Development for Bone Metastasis
Table 7: Number of Products under Development by Companies, Bone Metastasis
Table 8: Number of Products under Development by Universities/Institutes, Bone Metastasis
Table 9: Products under Development by Companies, Bone Metastasis
Table 10: Products under Development by Universities/Institutes, Bone Metastasis
Table 11: Number of Products under Development for Cancer Pain
Table 12: Number of Products under Development by Companies, Cancer Pain
Table 13: Number of Products under Development by Universities/Institutes, Cancer Pain
Table 14: Products under Development by Companies, Cancer Pain
Table 15: Products under Development by Universities/Institutes, Cancer Pain
Table 16: Number of Products by Stage and Target, Cancer Anorexia-Cachexia Syndrome
Table 17: Number of Products by Stage and Mechanism of Action, Cancer Anorexia-Cachexia Syndrome
Table 18: Number of Products by Stage and Route of Administration, Cancer Anorexia-Cachexia Syndrome
Table 19: Number of Products by Stage and Molecule Type, Cancer Anorexia-Cachexia Syndrome
Table 20: Number of Products by Stage and Target, Bone Metastasis
Table 21: Number of Products by Stage and Mechanism of Action, Bone Metastasis
Table 22: Number of Products by Stage and Route of Administration, Bone Metastasis
Table 23: Number of Products by Stage and Molecule Type, Bone Metastasis
Table 24: Number of Products by Stage and Target, Cancer Pain
Table 25: Number of Products by Stage and Mechanism of Action, Cancer Pain
Table 26: Number of Products by Stage and Route of Administration, Cancer Pain
Table 27: Number of Products by Stage and Molecule Type, Cancer Pain
Table 28: Cancer Anorexia-Cachexia Syndrome – Pipeline by Abreos Biosciences Inc
Table 29: Cancer Anorexia-Cachexia Syndrome – Pipeline by Acacia Pharma Ltd
Table 30: Cancer Anorexia-Cachexia Syndrome – Pipeline by Aeterna Zentaris Inc
Table 31: Cancer Anorexia-Cachexia Syndrome – Pipeline by Incyte Corp
Table 32: Cancer Anorexia-Cachexia Syndrome – Pipeline by Lakewood-Amedex Inc
Table 33: Cancer Anorexia-Cachexia Syndrome – Pipeline by Novartis AG
Table 34: Cancer Anorexia-Cachexia Syndrome – Pipeline by Paradigm Biopharmaceuticals Ltd
Table 35: Cancer Anorexia-Cachexia Syndrome – Pipeline by RaQualia Pharma Inc
Table 36: Cancer Anorexia-Cachexia Syndrome – Pipeline by Viking Therapeutics Inc
Table 37: Cancer Anorexia-Cachexia Syndrome – Pipeline by Zeria Pharmaceutical Co Ltd
Table 38: Bone Metastasis – Pipeline by Ablynx NV
Table 39: Bone Metastasis – Pipeline by Amgen Inc
Table 40: Bone Metastasis – Pipeline by Amura Holdings Ltd
Table 41: Bone Metastasis – Pipeline by BiologicsMD Inc
Table 42: Bone Metastasis – Pipeline by ChemoCentryx Inc
Table 43: Bone Metastasis – Pipeline by CSPC Pharmaceutical Group Limited
Table 44: Bone Metastasis – Pipeline by Deciphera Pharmaceuticals LLC
Table 45: Bone Metastasis – Pipeline by Eli Lilly and Co
Table 46: Bone Metastasis – Pipeline by Lupin Ltd
Table 47: Bone Metastasis – Pipeline by Mirati Therapeutics Inc
Table 48: Bone Metastasis – Pipeline by Oncobiologics Inc
Table 49: Bone Metastasis – Pipeline by Oncodrone BV
Table 50: Bone Metastasis – Pipeline by OPKO Health Inc
Table 51: Bone Metastasis – Pipeline by R Pharm
Table 52: Bone Metastasis – Pipeline by Redx Pharma Plc
Table 53: Bone Metastasis – Pipeline by Serene LLC
Table 54: Bone Metastasis – Pipeline by Taiho Pharmaceutical Co Ltd
Table 55: Bone Metastasis – Pipeline by Terpenoid Therapeutics Inc
Table 56: Cancer Pain – Pipeline by Alexza Pharmaceuticals Inc
Table 57: Cancer Pain – Pipeline by AngioChem Inc
Table 58: Cancer Pain – Pipeline by Aoxing Pharmaceutical Company Inc
Table 59: Cancer Pain – Pipeline by Aphios Corp
Table 60: Cancer Pain – Pipeline by AstraZeneca Plc
Table 61: Cancer Pain – Pipeline by ChironWells GmbH
Table 62: Cancer Pain – Pipeline by Colby Pharmaceutical Co
Table 63: Cancer Pain – Pipeline by ConSynance Therapeutics Inc
Table 64: Cancer Pain – Pipeline by Daewoong Pharmaceutical Co Ltd
Table 65: Cancer Pain – Pipeline by Daiichi Sankyo Co Ltd
Table 66: Cancer Pain – Pipeline by Dompe Farmaceutici SpA
Table 67: Cancer Pain – Pipeline by Fujimoto Pharmaceutical Corp
Table 68: Cancer Pain – Pipeline by Grunenthal GmbH
Table 69: Cancer Pain – Pipeline by Hisamitsu Pharmaceutical Co Inc
Table 70: Cancer Pain – Pipeline by Immupharma Plc
Table 71: Cancer Pain – Pipeline by Insys Therapeutics Inc
Table 72: Cancer Pain – Pipeline by IntelGenx Corp
Table 73: Cancer Pain – Pipeline by iX Biopharma Ltd
Table 74: Cancer Pain – Pipeline by Klaria Pharma Holding AB
Table 75: Cancer Pain – Pipeline by Komipharm International Co Ltd
Table 76: Cancer Pain – Pipeline by KPI Therapeutics Inc
Table 77: Cancer Pain – Pipeline by Medlab Clinical Ltd
Table 78: Cancer Pain – Pipeline by Nanomerics Ltd
Table 79: Cancer Pain – Pipeline by Neurocentrx Pharma Ltd
Table 80: Cancer Pain – Pipeline by Nippon Kayaku Co Ltd
Table 81: Cancer Pain – Pipeline by Orion Corporation
Table 82: Cancer Pain – Pipeline by Pain Therapeutics Inc
Table 83: Cancer Pain – Pipeline by Pfizer Inc
Table 84: Cancer Pain – Pipeline by Pharmaleads SA
Table 85: Cancer Pain – Pipeline by Recordati SpA
Table 86: Cancer Pain – Pipeline by Ribomic Inc
Table 87: Cancer Pain – Pipeline by Trillium Therapeutics Inc
Table 88: Cancer Pain – Pipeline by Virobay Inc
Table 89: Cancer Pain – Pipeline by WEX Pharmaceuticals Inc
Table 90: Cancer Anorexia-Cachexia Syndrome – Dormant Projects
Table 91: Bone Metastasis – Dormant Projects
Table 92: Cancer Pain – Dormant Projects
Table 93: Cancer Anorexia-Cachexia Syndrome – Discontinued Products
Table 94: Bone Metastasis – Discontinued Products
Table 95: Cancer Pain – Discontinued Products

List of Figures
Figure 1: Number of Products under Development for Cancer Anorexia-Cachexia Syndrome
Figure 2: Number of Products under Development by Companies, Cancer Anorexia-Cachexia Syndrome
Figure 3: Number of Products under Development by Universities/Institutes, Cancer Anorexia-Cachexia Syndrome
Figure 4: Number of Products under Development for Bone Metastasis
Figure 5: Number of Products under Development by Companies, Bone Metastasis
Figure 6: Number of Products under Development by Universities/Institutes, Bone Metastasis
Figure 7: Number of Products under Development for Cancer Pain
Figure 8: Number of Products under Development by Companies, Cancer Pain
Figure 9: Number of Products by Top 10 Targets, Cancer Anorexia-Cachexia Syndrome
Figure 10: Number of Products by Stage and Top 10 Targets, Cancer Anorexia-Cachexia Syndrome
Figure 11: Number of Products by Top 10 Mechanism of Actions, Cancer Anorexia-Cachexia Syndrome
Figure 12: Number of Products by Stage and Top 10 Mechanism of Actions, Cancer Anorexia-Cachexia Syndrome
Figure 13: Number of Products by Routes of Administration, Cancer Anorexia-Cachexia Syndrome
Figure 14: Number of Products by Stage and Routes of Administration, Cancer Anorexia-Cachexia Syndrome
Figure 15: Number of Products by Molecule Types, Cancer Anorexia-Cachexia Syndrome
Figure 16: Number of Products by Stage and Molecule Types, Cancer Anorexia-Cachexia Syndrome
Figure 17: Number of Products by Top 10 Targets, Bone Metastasis
Figure 18: Number of Products by Stage and Top 10 Targets, Bone Metastasis
Figure 19: Number of Products by Top 10 Mechanism of Actions, Bone Metastasis
Figure 20: Number of Products by Stage and Top 10 Mechanism of Actions, Bone Metastasis
Figure 21: Number of Products by Routes of Administration, Bone Metastasis
Figure 22: Number of Products by Stage and Routes of Administration, Bone Metastasis
Figure 23: Number of Products by Molecule Types, Bone Metastasis
Figure 24: Number of Products by Stage and Molecule Types, Bone Metastasis
Figure 25: Number of Products by Top 10 Targets, Cancer Pain
Figure 26: Number of Products by Stage and Top 10 Targets, Cancer Pain
Figure 27: Number of Products by Top 10 Mechanism of Actions, Cancer Pain
Figure 28: Number of Products by Stage and Top 10 Mechanism of Actions, Cancer Pain
Figure 29: Number of Products by Routes of Administration, Cancer Pain
Figure 30: Number of Products by Stage and Routes of Administration, Cancer Pain
Figure 31: Number of Products by Molecule Types, Cancer Pain
Figure 32: Number of Products by Stage and Molecule Types, Cancer Pain

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Cancer Supportive Care Report Coverage
2.2 Cancer Anorexia-Cachexia Syndrome – Overview
2.3 Bone Metastasis – Overview
2.4 Cancer Pain – Overview
3 Therapeutics Development
3.1 Cancer Anorexia-Cachexia Syndrome
3.2 Bone Metastasis
3.3 Cancer Pain
4 Therapeutics Assessment
4.1 Cancer Anorexia-Cachexia Syndrome
4.2 Bone Metastasis
4.3 Cancer Pain
5 Companies Involved in Therapeutics Development
5.1 Cancer Anorexia-Cachexia Syndrome
5.2 Bone Metastasis
5.3 Cancer Pain
6 Dormant Projects
6.1 Cancer Anorexia-Cachexia Syndrome
6.2 Bone Metastasis
6.3 Cancer Pain
7 Discontinued Products
7.1 Cancer Anorexia-Cachexia Syndrome
7.2 Bone Metastasis
7.3 Cancer Pain
8 Product Development Milestones
8.1 Cancer Anorexia-Cachexia Syndrome
8.2 Bone Metastasis
8.3 Cancer Pain
9 Appendix
9.1 Methodology
9.2 Coverage
9.3 Secondary Research
9.4 Primary Research
9.5 Expert Panel Validation
9.6 Contact Us
9.7 Disclaimer

1.1 List of Tables
Table 1: Number of Products under Development for Cancer Anorexia-Cachexia Syndrome
Table 2: Number of Products under Development by Companies, Cancer Anorexia-Cachexia Syndrome
Table 3: Number of Products under Development by Universities/Institutes, Cancer Anorexia-Cachexia Syndrome
Table 4: Products under Development by Companies, Cancer Anorexia-Cachexia Syndrome
Table 5: Products under Development by Universities/Institutes, Cancer Anorexia-Cachexia Syndrome
Table 6: Number of Products under Development for Bone Metastasis
Table 7: Number of Products under Development by Companies, Bone Metastasis
Table 8: Number of Products under Development by Universities/Institutes, Bone Metastasis
Table 9: Products under Development by Companies, Bone Metastasis
Table 10: Products under Development by Universities/Institutes, Bone Metastasis
Table 11: Number of Products under Development for Cancer Pain
Table 12: Number of Products under Development by Companies, Cancer Pain
Table 13: Number of Products under Development by Universities/Institutes, Cancer Pain
Table 14: Products under Development by Companies, Cancer Pain
Table 15: Products under Development by Universities/Institutes, Cancer Pain
Table 16: Number of Products by Stage and Target, Cancer Anorexia-Cachexia Syndrome
Table 17: Number of Products by Stage and Mechanism of Action, Cancer Anorexia-Cachexia Syndrome
Table 18: Number of Products by Stage and Route of Administration, Cancer Anorexia-Cachexia Syndrome
Table 19: Number of Products by Stage and Molecule Type, Cancer Anorexia-Cachexia Syndrome
Table 20: Number of Products by Stage and Target, Bone Metastasis
Table 21: Number of Products by Stage and Mechanism of Action, Bone Metastasis
Table 22: Number of Products by Stage and Route of Administration, Bone Metastasis
Table 23: Number of Products by Stage and Molecule Type, Bone Metastasis
Table 24: Number of Products by Stage and Target, Cancer Pain
Table 25: Number of Products by Stage and Mechanism of Action, Cancer Pain
Table 26: Number of Products by Stage and Route of Administration, Cancer Pain
Table 27: Number of Products by Stage and Molecule Type, Cancer Pain
Table 28: Cancer Anorexia-Cachexia Syndrome – Pipeline by Abreos Biosciences Inc
Table 29: Cancer Anorexia-Cachexia Syndrome – Pipeline by Acacia Pharma Ltd
Table 30: Cancer Anorexia-Cachexia Syndrome – Pipeline by Aeterna Zentaris Inc
Table 31: Cancer Anorexia-Cachexia Syndrome – Pipeline by Incyte Corp
Table 32: Cancer Anorexia-Cachexia Syndrome – Pipeline by Lakewood-Amedex Inc
Table 33: Cancer Anorexia-Cachexia Syndrome – Pipeline by Novartis AG
Table 34: Cancer Anorexia-Cachexia Syndrome – Pipeline by Paradigm Biopharmaceuticals Ltd
Table 35: Cancer Anorexia-Cachexia Syndrome – Pipeline by RaQualia Pharma Inc
Table 36: Cancer Anorexia-Cachexia Syndrome – Pipeline by Viking Therapeutics Inc
Table 37: Cancer Anorexia-Cachexia Syndrome – Pipeline by Zeria Pharmaceutical Co Ltd
Table 38: Bone Metastasis – Pipeline by Ablynx NV
Table 39: Bone Metastasis – Pipeline by Amgen Inc
Table 40: Bone Metastasis – Pipeline by Amura Holdings Ltd
Table 41: Bone Metastasis – Pipeline by BiologicsMD Inc
Table 42: Bone Metastasis – Pipeline by ChemoCentryx Inc
Table 43: Bone Metastasis – Pipeline by CSPC Pharmaceutical Group Limited
Table 44: Bone Metastasis – Pipeline by Deciphera Pharmaceuticals LLC
Table 45: Bone Metastasis – Pipeline by Eli Lilly and Co
Table 46: Bone Metastasis – Pipeline by Lupin Ltd
Table 47: Bone Metastasis – Pipeline by Mirati Therapeutics Inc
Table 48: Bone Metastasis – Pipeline by Oncobiologics Inc
Table 49: Bone Metastasis – Pipeline by Oncodrone BV
Table 50: Bone Metastasis – Pipeline by OPKO Health Inc
Table 51: Bone Metastasis – Pipeline by R Pharm
Table 52: Bone Metastasis – Pipeline by Redx Pharma Plc
Table 53: Bone Metastasis – Pipeline by Serene LLC
Table 54: Bone Metastasis – Pipeline by Taiho Pharmaceutical Co Ltd
Table 55: Bone Metastasis – Pipeline by Terpenoid Therapeutics Inc
Table 56: Cancer Pain – Pipeline by Alexza Pharmaceuticals Inc
Table 57: Cancer Pain – Pipeline by AngioChem Inc
Table 58: Cancer Pain – Pipeline by Aoxing Pharmaceutical Company Inc
Table 59: Cancer Pain – Pipeline by Aphios Corp
Table 60: Cancer Pain – Pipeline by AstraZeneca Plc
Table 61: Cancer Pain – Pipeline by ChironWells GmbH
Table 62: Cancer Pain – Pipeline by Colby Pharmaceutical Co
Table 63: Cancer Pain – Pipeline by ConSynance Therapeutics Inc
Table 64: Cancer Pain – Pipeline by Daewoong Pharmaceutical Co Ltd
Table 65: Cancer Pain – Pipeline by Daiichi Sankyo Co Ltd
Table 66: Cancer Pain – Pipeline by Dompe Farmaceutici SpA
Table 67: Cancer Pain – Pipeline by Fujimoto Pharmaceutical Corp
Table 68: Cancer Pain – Pipeline by Grunenthal GmbH
Table 69: Cancer Pain – Pipeline by Hisamitsu Pharmaceutical Co Inc
Table 70: Cancer Pain – Pipeline by Immupharma Plc
Table 71: Cancer Pain – Pipeline by Insys Therapeutics Inc
Table 72: Cancer Pain – Pipeline by IntelGenx Corp
Table 73: Cancer Pain – Pipeline by iX Biopharma Ltd
Table 74: Cancer Pain – Pipeline by Klaria Pharma Holding AB
Table 75: Cancer Pain – Pipeline by Komipharm International Co Ltd
Table 76: Cancer Pain – Pipeline by KPI Therapeutics Inc
Table 77: Cancer Pain – Pipeline by Medlab Clinical Ltd
Table 78: Cancer Pain – Pipeline by Nanomerics Ltd
Table 79: Cancer Pain – Pipeline by Neurocentrx Pharma Ltd
Table 80: Cancer Pain – Pipeline by Nippon Kayaku Co Ltd
Table 81: Cancer Pain – Pipeline by Orion Corporation
Table 82: Cancer Pain – Pipeline by Pain Therapeutics Inc
Table 83: Cancer Pain – Pipeline by Pfizer Inc
Table 84: Cancer Pain – Pipeline by Pharmaleads SA
Table 85: Cancer Pain – Pipeline by Recordati SpA
Table 86: Cancer Pain – Pipeline by Ribomic Inc
Table 87: Cancer Pain – Pipeline by Trillium Therapeutics Inc
Table 88: Cancer Pain – Pipeline by Virobay Inc
Table 89: Cancer Pain – Pipeline by WEX Pharmaceuticals Inc
Table 90: Cancer Anorexia-Cachexia Syndrome – Dormant Projects
Table 91: Bone Metastasis – Dormant Projects
Table 92: Cancer Pain – Dormant Projects
Table 93: Cancer Anorexia-Cachexia Syndrome – Discontinued Products
Table 94: Bone Metastasis – Discontinued Products
Table 95: Cancer Pain – Discontinued Products

1.2 List of Figures
Figure 1: Number of Products under Development for Cancer Anorexia-Cachexia Syndrome
Figure 2: Number of Products under Development by Companies, Cancer Anorexia-Cachexia Syndrome
Figure 3: Number of Products under Development by Universities/Institutes, Cancer Anorexia-Cachexia Syndrome
Figure 4: Number of Products under Development for Bone Metastasis
Figure 5: Number of Products under Development by Companies, Bone Metastasis
Figure 6: Number of Products under Development by Universities/Institutes, Bone Metastasis
Figure 7: Number of Products under Development for Cancer Pain
Figure 8: Number of Products under Development by Companies, Cancer Pain
Figure 9: Number of Products by Top 10 Targets, Cancer Anorexia-Cachexia Syndrome
Figure 10: Number of Products by Stage and Top 10 Targets, Cancer Anorexia-Cachexia Syndrome
Figure 11: Number of Products by Top 10 Mechanism of Actions, Cancer Anorexia-Cachexia Syndrome
Figure 12: Number of Products by Stage and Top 10 Mechanism of Actions, Cancer Anorexia-Cachexia Syndrome
Figure 13: Number of Products by Routes of Administration, Cancer Anorexia-Cachexia Syndrome
Figure 14: Number of Products by Stage and Routes of Administration, Cancer Anorexia-Cachexia Syndrome
Figure 15: Number of Products by Molecule Types, Cancer Anorexia-Cachexia Syndrome
Figure 16: Number of Products by Stage and Molecule Types, Cancer Anorexia-Cachexia Syndrome
Figure 17: Number of Products by Top 10 Targets, Bone Metastasis
Figure 18: Number of Products by Stage and Top 10 Targets, Bone Metastasis
Figure 19: Number of Products by Top 10 Mechanism of Actions, Bone Metastasis
Figure 20: Number of Products by Stage and Top 10 Mechanism of Actions, Bone Metastasis
Figure 21: Number of Products by Routes of Administration, Bone Metastasis
Figure 22: Number of Products by Stage and Routes of Administration, Bone Metastasis
Figure 23: Number of Products by Molecule Types, Bone Metastasis
Figure 24: Number of Products by Stage and Molecule Types, Bone Metastasis
Figure 25: Number of Products by Top 10 Targets, Cancer Pain
Figure 26: Number of Products by Stage and Top 10 Targets, Cancer Pain
Figure 27: Number of Products by Top 10 Mechanism of Actions, Cancer Pain
Figure 28: Number of Products by Stage and Top 10 Mechanism of Actions, Cancer Pain
Figure 29: Number of Products by Routes of Administration, Cancer Pain
Figure 30: Number of Products by Stage and Routes of Administration, Cancer Pain
Figure 31: Number of Products by Molecule Types, Cancer Pain
Figure 32: Number of Products by Stage and Molecule Types, Cancer Pain

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

This report provides an overview of the Cancer Supportive Care pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for cancer anorexia-cachexia syndrome, bone metastasis and cancer pain, and features dormant and discontinued projects.

Anorexia is defined as the loss of the desire to eat. Progressive wasting is common in many types of cancer and is one of the most important factors leading to early death in cancer patients. Advanced cancer undergo a wasting syndrome associated with cancer anorexia-cachexia and asthenia, which is associated with weakness, fatigue, and a poor quality of life. There are a total of XX products in development for this indication, by XX companies and four academic institutions.

Bone metastasis occurs when cancer cells spread from their original site to a bone. Signs and symptoms of bone metastasis include bone pain, broken bones, urinary incontinence, bowel incontinence and weakness in the legs. There are a total of XX products in development for this   indication, by XX companies and four academic institutions. Key companies operating in this pipeline   space include MetCure Therapeutics, Applied Integrin Sciences, Eli Lilly, and Tel Aviv University.

Cancer pain can be defined as a complex sensation that reflects both damage to the body and the body's response to the damage. Pain may arise due to tumor compressing or infiltrating tissue, from treatments and diagnostic procedures, or from skin, nerve and other changes caused by either the body's immune response or hormones released by the tumor. There are a total of XX products in development for this indication, by XX companies and four academic institutions. Key companies operating in this pipeline space include Komipharm, Trillium Therapeutics, AstraZeneca, Insys Therapeutics, Klaria Pharma and Pharmaleads.

The majority of products in cancer anorexia-cachexia syndrome target the growth hormone secretagogue receptor type 1, although there are a range of other molecular targets in development.   Within bone metastasis, the most common molecular targets are the tumor necrosis factor ligand   superfamily member XX and the hepatocyte growth factor receptor, along with a range of others.   Finally, within cancer pain, neurotransmitters such as the mu type opioid receptor, and a range o channels, are the most common type of target, reflecting the pain treatment landscape in general.

Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll